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Edited by George DeMartinoVon Hippel–Lindau (VHL) disease is characterized by
frequent mutation of VHL protein, a tumor suppressor that
functions as the substrate recognition subunit of a Cullin2
RING E3 ligase complex (CRL2VHL). CRL2VHL plays important
roles in oxygen sensing by targeting hypoxia-inducible factor-
alpha (HIF-α) subunits for ubiquitination and degradation.
VHL is also commonly hijacked by bifunctional molecules such
as proteolysis-targeting chimeras to induce degradation of
target molecules. We previously reported the design and
characterization of VHL inhibitors VH032 and VH298 that
block the VHL:HIF-α interaction, activate the HIF transcrip-
tion factor, and induce a hypoxic response, which can be
beneficial to treat anemia and mitochondrial diseases. How
these compounds affect the global cellular proteome remains
unknown. Here, we use unbiased quantitative MS to identify
the proteomic changes elicited by the VHL inhibitor compared
with hypoxia or the broad-spectrum prolyl-hydroxylase
domain enzyme inhibitor IOX2. Our results demonstrate that
VHL inhibitors selectively activate the HIF response similar to
the changes induced in hypoxia and IOX2 treatment. Inter-
estingly, VHL inhibitors were found to specifically upregulate
VHL itself. Our analysis revealed that this occurs via protein
stabilization of VHL isoforms and not via changes in transcript
levels. Increased VHL levels upon VH298 treatment resulted in
turn in reduced levels of HIF-1α protein. This work demon-
strates the specificity of VHL inhibitors and reveals different
antagonistic effects upon their acute versus prolonged treat-
ment in cells. These findings suggest that therapeutic use of
VHL inhibitors may not produce overt side effects from HIF
stabilization as previously thought.
The von Hippel–Lindau (VHL) tumor suppressor is a
multisubunit Cullin RING E3 ligase (CRL2VHL)—composed of
Cullin2 as the central scaffold subunit, Rbx1 as RING subunit,
ElonginB and ElonginC as adaptor subunits, and VHL as
substrate recognition subunit (1, 2). VHL functions to specif-
ically bind hydroxylated hypoxia-inducible factor 1-alpha
(HIF-1α), mediating polyubiquitination and subsequent* For correspondence: Alessio Ciulli, a.ciulli@dundee.ac.uk; Sonia Rocha,
srocha@liverpool.ac.uk.
© 2021 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for
BY license (http://creativecommons.org/licenses/by/4.0/).targeting of HIF-1α for proteasomal degradation (3). HIFs are
transcription factors that regulate the response to reduced
oxygen (O2) availability termed hypoxia. HIF is composed of
an O2-insensitive β-subunit (HIF-β) that is stable, and an O2-
labile α subunit, of which three isoforms are known: HIF-1α,
HIF-2α, and HIF-3α. The recognition and ubiquitination of
HIF-α subunits by VHL is dependent on proline hydroxylation
of the O2-dependent degradation domain of HIF-α, a post-
translational modification mediated by 2-oxoglutarate, iron
(II) dioxygenases called prolyl-hydroxylases (PHDs). Proline
hydroxylation results in a high-affinity binding of HIF-α to
VHL and thus subsequent ubiquitination and proteasomal
degradation of HIF-α under normal O2 conditions (3).
Mutations in human VHL result in a number of abnor-
malities, collectively called VHL disease when occurring in the
germ line (4). However, VHL is also often loss in clear cell
renal cell carcinoma (5). The fact that VHL is a tumor sup-
pressor protein, and that VHL loss is found in clear cell renal
cell carcinoma tumors, have led to the hypothesis that VHL
would not be a good target to inhibit and that chronic HIF
stabilization by VHL inhibitors might have detrimental side
effects (6). Apart from HIF, other substrates for VHL have
been postulated (7). These include Aurora A, ZHX2, NDRG3,
and B-Myb (8–11). Understanding VHL functions and the
pharmacology of HIF stabilizers and hypoxia inducers is thus
important in a variety of physiological and pathological con-
ditions (12).
We had previously developed several compounds, able to
selectively bind to and inhibit VHL (13, 14). Of these, VH298 is
a potent chemical probe that triggers the hypoxic response via
a different mechanism to other HIF stabilizers, that is, by
blocking the VHL:HIF-α protein–protein interaction down-
stream of HIF-α hydroxylation (13). We have also character-
ized the activity of a related compound VH032 (15), in its
ability to induce the transcriptional response to hypoxia and
how this compares to hypoxia (1% O2) or PHD inhibition
using an unbiased RNA-Seq approach (16). VH298 has also
been used to trigger the hypoxic response in mice, demon-
strating its appropriateness for in vivo applications (17, 18). In
distinct applications, VHL ligands are widely used as part of
heterobifunctional degrader molecules known as proteolysis-
targeting chimeras (PROTACs) (19–21). We and others haveJ. Biol. Chem. (2021) 297(2) 100910 1
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VHL induction by inhibitorextensively demonstrated the use of VHL ligands VH032 and
VH298 in PROTACs targeting Bromodomain and extra-ter-
minalproteins (22–24), protein kinases (25–27) among many
other target proteins, including E3 ligases themselves as
demonstrated by VHL homo-PROTACs (28).
Given the widespread use and applications of VHL ligands,
inhibitors, and VHL-based PROTACs, it is important to un-
derstand the effect of VHL inhibition to the intracellular
proteome in an unbiased fashion. Here, we investigate how
VHL inhibitors alter the proteome of cells, using quantitative
tandem mass tag (TMT) labeling–based MS. We compare
these alterations to those occurring after hypoxia or exposure
to a 2-oxoglutarate dioxygenase inhibitor, IOX2. We show that
VH032 and its more potent related compound, VH298, in-
crease VHL protein levels—an increase that is not observed
following hypoxia or IOX2 treatment. Increases in VHL pro-
tein levels are due to stabilization of specific VHL isoforms and
not alteration of mRNA. VHL protein increases result in
reduction of HIF levels following prolonged VH298 treatment
in cells.Results
Proteomic analysis of different HIF stabilizing agents
We have recently published our unbiased mRNA-Seq
analysis of several HIF-stabilizing agents, including hypox-
ia, a broad-spectrum PHD inhibitor (IOX2), and a VHL in-
hibitor (VH032) (Fig. 1A) (16). In addition, we had
characterized the cellular responses to a more potent and
specific VHL inhibitor called VH298 (13, 14, 16). To gain a
better understanding of the effect of inhibition of VHL by the
small-molecule VHL inhibitor, global proteome analysis was
performed in an unbiased manner. In a similar approach to
our RNA-Seq analysis, HeLa cells were treated with 250 μM
VH032, comparing with vehicle control (0.5% dimethyl
sulfoxide [DMSO]), hypoxia (1% O2), and PHD inhibitor
(250 μM IOX2). Enabled by the 10-plex TMT labeling–based
strategy, a total of four conditions were performed in
duplicate with the treatment time of 24 h, a time point long
enough to observe the global proteome changes induced by
HIF and any other changes elicited by the VHL inhibitor
(Fig. 1B). By use of the MS–based method, more than 8043
proteins were identified with a false discovery rate <0.01 and
quantified (Table S1).
We next determined the reproducibility between the two
replicates by plotting the relative abundance for each protein
to respective DMSO control between the two replicates
(Fig. 1C). Hypoxia treatment showed the highest level of
similarity in the proteins identified and quantified (Pearson
correlation: 0.81); this was followed by IOX2 and VH032
treatments (Pearson correlation: 0.43 and 0.30, respectively).
The mode of acquisition for the analysis is data dependent,
which intrinsically generates variability within experiments
(29). The lower correlation for the chemical inhibitors
compared with hypoxia could be due to variability of inhibitor
exposure across cells, but more work is needed to formally
investigate this further. Analysis of the proteome changes2 J. Biol. Chem. (2021) 297(2) 100910identified revealed that the majority of upregulated proteins
induced by VHL inhibitor were also identified in the hypoxia
and IOX2 treatments, sharing 26 targets (Fig. 1D and Table 1).
Of these, 22 genes were also identified in our RNA-Seq anal-
ysis, indicating changes to transcription vastly dependent on
HIF (highlighted in Table 1). Of the additional four proteins
shared by all these stimuli, notably HIF-1α is present, and
other proteins are cholecystokinin, ryanodine receptor 3, and
caspase recruitment domain family member 11.
As expected, hypoxia induced the biggest changes in the
proteome, including both induced and repressed protein
expression (Fig. 1D and Table S2). This was also reflected in
the mRNA-Seq analysis (16). In addition, more specific HIF
inducers such as the VHL inhibitor and to some extent IOX2
broadly resulted in increased protein expression, with very few
proteins found to be reduced in level (Fig. 1D and Table S2).
This is in line with the knowledge that HIF is associated with
gene induction and normally does not act as a transcriptional
repressor (30).VHL inhibitors increase intracellular VHL protein levels
As we are particularly interested in the specificity of the
VHL inhibitor, we turned our attention to the two proteins
solely induced by VH032 compound: amylase 1 (AMY1) and
VHL. AMY1 is a protein previously shown to be induced by
hypoxia in plants (31), so strictly not associated with VHL
inhibition only. We therefore turned our attention to VHL
itself. VHL protein abundance increased upon VHL inhibitor
treatment but not PHD inhibitor or hypoxia (Fig. 2, A and B).
Relative to DMSO control, protein abundance of VHL
increased to 1.59 for the first replicate and 1.53 for the second
replicate (Fig. 2A). In contrast, VHL protein abundance was
unchanged in IOX2 (1.02 for replicate 1 and 0.94 for replicate
2) and decreased slightly in hypoxia (0.87 for replicate 1 and
0.89 for replicate 2).
To validate the observation of the increase of VHL in the
presence of VH032, we monitored VHL protein levels in HeLa
cells treated with VH032 by Western blot. VHL protein levels
did not increase after a short treatment of 2 h but showed
marked increase in response to a longer treatment of 24 h with
VH032 (Fig. 2C). In the course of the investigation, we iden-
tified and characterized a more potent VHL inhibitor, with
enhanced cell permeability and cellular activity (VH298;
Fig. 2D) that we qualified as a chemical probe (13, 14). Inside
cells, VH298 completely disrupted the binding between HIF-
1α and VHL, as shown in coimmunoprecipitation experiments
(Fig. 2E). Therefore, we selected VH298 in our study moving
forward. Like VH032, VH298 treatment resulted in increase in
VHL protein levels (Fig. 2F), also in a time-dependent manner,
confirming that this increase is due to the inhibition of VHL by
the small molecules. In addition, the increase in VHL protein
levels was not observed with the nonbinding epimer cisVH298
(Fig. 2, G and H), further demonstrating that accumulation of
VHL results specifically from small-molecule binding to VHL.
VH298 also increased VHL protein levels in another cell
context, human foreskin fibroblasts (HFFs) (Fig. 2H). In both
Figure 1. Unbiased proteomics identify VHL protein level increase upon VHL inhibitor treatment. A, chemical structures of IOX2 and VH032. B, di-
agram depicting the workflow of tandem mass tag (TMT) labeling. HeLa cells were treated with 0.5% DMSO, 1% O2 (hypoxia), 250 μM IOX2, and 250 μM
VH032 for 24 h—in biological duplicate. Proteins were obtained by cell lysis, cleaned up, digested by trypsinization, and labeled with 10-plex TMT labeling
reagent. Labeled peptides were combined, desalted, fractionated, and analyzed by MS. Red text indicates steps carried out at the protein level, and blue text
indicates steps performed on peptides. C, scatter plot representation of relative protein abundances obtained for different treatment conditions compared
with respective replicate of vehicle (DMSO)-treated cells, for a total of 8043 proteins quantified. The two axes are relative abundance (log2FC) from two
different replicates in this experiment. Red dots represent upregulated genes in both replicates (absolute fold-change difference to DMSO > 1.3), and blue
dots represent downregulated genes in both replicates (absolute fold-change difference to DMSO < 0.7). Red line is the linear fit to the data. D, Venn
diagrams depicting the number of upregulated genes and downregulated genes in the two replicates comparing the presence of hypoxia, IOX2, or VH032
to DMSO control. DMSO, dimethyl sulfoxide; VHL, Von Hippel–Lindau.
VHL induction by inhibitorHeLa and HFF cells, the treatment of hypoxia or PHD inhib-
itor IOX2 did not increase VHL protein levels (Fig. 2, G and
H), in agreement with the proteomic results (Fig. 2, A and B).
We also confirmed that treatment with FG-4592, which is a
more specific PHD inhibitor, showed similar results to those
obtained with IOX2—namely no alteration in VHL protein
levels. Altogether, VHL protein levels were confirmed to be
increased by the small-molecule VHL inhibitors, not only in
HeLa cells, in which the proteomic analysis was performed,but also in HFFs, and this increase was not observed following
hypoxia or in the presence of PHD inhibitors.Ligand-bound VHL increases protein stability
We next asked whether the increase in VHL protein levels in
the presence of VHL inhibitor was due to the increase in mRNA
levels. In quantitative RT-PCR assays monitoring VHL mRNA,
mRNA levels of VHL were not altered in the presence of VH032J. Biol. Chem. (2021) 297(2) 100910 3
Table 1
List of proteins upregulated in hypoxia, IOX2, and VH032 treatment
Uniprot ID Gene name
Hypoxia







Q12983 BNIP3 18.11 3.33 11.59 2.6 8.33 2.03
P35318 ADML 6.47 4.73 2.05 4.81 1.47 3.44
O76061 STC2 3.24 1.59 1.58 4.36 1.84 1.31
P11169 GTR3 7.52 6.58 1.39 2.51 1.63 1.95
Q16790 CAH9 6.76 6.04 3.31 3.93 3.94 3.26
P06307 CCKN 1.43 2.46 1.71 1.8 1.35 1.98
Q16665 HIF1A 4 2.31 2.37 3.68 2.19 1.98
Q15413 RYR3 2.32 1.87 2.2 2.86 1.45 4.3
P98155 VLDLR 3.51 2.6 2.01 3.45 1.97 1.85
P05412 JUN 2.89 1.94 1.34 2.03 1.32 1.37
Q16877 F264 6.29 4.48 1.85 2.97 2.1 2.09
P11166 GTR1 3.59 2.79 1.35 1.72 1.47 1.42
Q9Y4K0 LOXL2 3.89 2.96 1.3 2.11 1.46 1.44
Q9BXL7 CAR11 2.13 1.72 1.85 2.33 1.56 3.23
Q9NX57 RAB20 2.5 1.93 1.44 2.34 1.58 1.49
P28300 LYOX 4.81 3.63 1.59 4.38 1.44 1.72
Q92597 NDRG1 5.06 4.25 1.36 1.58 1.62 1.41
B7ZBB8 PP13G 4.37 3.65 1.57 1.84 1.73 1.37
P13674 P4HA1 2.45 2.31 1.48 1.53 1.5 1.58
Q15118 PDK1 2.07 1.84 1.62 1.63 1.61 1.54
P09104 ENOG 3.03 2.62 1.39 2.23 1.7 1.74
Q9Y4C1 KDM3A 2.53 2.23 1.46 1.47 1.56 1.44
P27144 KAD4 1.42 1.38 1.31 1.38 1.33 1.37
O00469 PLOD2 2.76 2.53 1.41 1.5 1.55 1.58
Q9GZT9 EGLN1 1.87 1.61 1.37 1.44 1.39 1.34
Q9Y5U4 INSI2 2.19 2.18 1.31 2.39 1.32 1.54
Proteins were selected at a false discovery rate <0.01 and relative abundance to control DMSO >1.3 for each replicate. Uniprot ID and gene name are listed with relative abundance to DMSO control. In italics: transcripts of these












Figure 2. VHL protein levels increase in the presence of VHL inhibitors. A, relative abundance and B, graph depicting relative VHL protein abundance
with a false discovery rate <0.01 comparing with DMSO control for hypoxia, IOX2, and VH032 treatments after 24 h. B, data are presented as means + SD
from proteomic analysis (TMT labeling) of two independent biological experiments. Two-tailed Student’s t test was performed to calculate p values, and
levels of significance are denoted as follows: **0.001 < p < 0.01 and, ns: p > 0.05. HeLa cells were treated with (C) 250 μM VH032 or (F) 100 μM VH298 for
indicated time. D, chemical structure of VH298. E, coimmunoprecipitation on lysates from HeLa cells treated with vehicle DMSO (0.5% for 3 h), VH298
(100 μM for 2 h), MG132 (20 μM for 3 h), or VH298 and MG132 (100 μM VH298 for 2 h and 20 μM MG132 for 3 h) before lysis. About 300 μg of protein were
used to immunoprecipitate with the 2 μg HIF-1α antibody (Santa Cruz; sc-53546). Mouse immunoglobulin G (IgG; 2 μg) was used as a control. Inputs
represent 10% of the starting material used per immunoprecipitation (IP). G, HeLa or (H) HFF cells were treated with 0.5% DMSO, hypoxia (1% O2), and
100 μM of indicated compounds for 24 h. 786-O cell lysate was loaded in (H) as negative control for VHL bands. Protein levels were analyzed by
immunoblotting using antibodies against HIF-1α, VHL, and β-actin, which acted as a loading control. HIF-1α* denotes longer exposure. The blots shown are
representative of three independent experiments. DMSO, dimethyl sulfoxide; HFF, human foreskin fibroblast; HIF-1α, hypoxia-inducible factor-1α; VHL, Von
Hippel–Lindau.
VHL induction by inhibitoror VH298 in HeLa (Fig. 3A) or VH298 in HFF cells (Fig. 3B).
Similar to the unaltered VHL protein levels, hypoxia and IOX2
did not induce changes in VHLmRNA levels (Fig. 3B). We next
examined whether VHL might be autoregulating itself to be
degraded by the proteasome, similar to how VHL regulates the
proteasomal degradation of HIF-1α. However, results showed
that VHL protein levels did not increase in the presence of
proteasome inhibitor MG132 (Fig. 3C). We next asked whether
the ligand-bound VHL might be more stable than the unbound
form. We performed a cycloheximide chase experiment that
inhibits de novo protein synthesis and monitored endogenousVHL protein levels to determine if the half-life of VHL increased
in the presence of VHL inhibitor. Analysis revealed increased
half-lives of both the long isoform of VHL and the short isoform
(Fig. 3, D and E). VHL encodes two major VHL isoforms: a 213-
amino acid isoform (pVHL1–213) and a 160-amino acid isoform
(pVHL54–213) (32, 33). These two isoforms are also referred as
pVHL30 and pVHL19, based on their apparentmolecularmasses
upon protein electrophoresis. pVHL19 arises from an internal
alternative translation initiation from Met54 within the open
reading frame of VHL and thereby missing the N-terminal




Figure 3. VHL inhibitor stabilizes VHL proteins at a post-translation level. VHL mRNA expressions in (A) HeLa cells treated with 0.5% DMSO, hypoxia
(1% O2), and 250 μM IOX2, 250 μM VH032, or 100 μM VH298 for 16 h or in (B) HFF cells treated with 0.5% DMSO or 100 μM VH298 for 24 h. mRNA was
collected, reverse transcribed, and analyzed by quantitative RT-PCR. The shown levels of the indicated mRNAs were normalized to those of β-actin. Graphs
depict the mean + SEM of three independent biological replicates. Two-tailed Student’s t test was performed to calculate p values, and levels of significance
are denoted as follows: ns is p > 0.05. C, HeLa cells treated with 20 μM MG132 for 3 h. 786-O cell lysate was loaded as negative control for VHL and HIF-1α.
D, half-life of VHL proteins of HeLa cells treated with DMSO negative control or VH298 VHL inhibitor was measured by treating cells with cycloheximide
(CHX) for indicated times. E, protein levels of VHL30 and VH19 were quantified from multiple blots of different exposure time by ImageJ and plotted. Protein
levels were analyzed by immunoblotting using antibodies against HIF-1α, VHL, and β-actin, which acted as a loading control. The blots shown are
representative of three independent experiments. DMSO, dimethyl sulfoxide; HFF, human foreskin fibroblast; HIF-1α, hypoxia-inducible factor-1α; VHL, von
Hippel–Lindau.
VHL induction by inhibitorVH298 increased the half-life of pVHL30 from 4 to 6 h, whereas
the half-life of VH298-bound pVHL19 increased to beyond the
6 h cycloheximide treatment. This result correlates to the
increased protein levels for pVHL30 and pVHL19 seen in the
presence of VHL inhibitors (Fig. 2, C and F–H). Taken together,
these data indicate that the binding of VHL inhibitor leads to
increased VHL protein levels, as a result of protein stabilization,
and delayed intracellular degradation.The VH298-induced VHL enhances proteasomal degradation
of HIF-1α in prolonged VH298 treatment
We have previously observed that HIF-1α protein levels are
acutely upregulated in the presence of VH298 because of6 J. Biol. Chem. (2021) 297(2) 100910inhibition of the VHL:HIF-α interaction, but this upregulation
is not sustained in prolonged treatment and eventually
decreased over time (Fig. 2F) (13). Since VHL protein levels
increased in the presence of its inhibitor, we hypothesize that
the decrease of HIF-1α levels observed in prolonged treatment
of VHL inhibitor could be due to the increase of VHL protein
levels. First, we investigated whether we could rescue the
degraded HIF-1α by adding more VH298 to further inhibit the
stabilized VHL. We determined the optimum concentration of
VH298 to induce the maximum level of HIF-1α, and the doses
were found to be 400 and 100 μM in HeLa and HFF cells,
respectively (Fig. 4A). The optimum concentration of VH298
was then added to respective cells that had been treated with






Figure 4. The decrease of HIF-1α protein levels in prolonged VH298 treatment is mediated by proteasomal degradation in a VHL-dependent
manner. A, dose-dependent immunoblots of HIF-1α in HeLa (left panel) and HFF (right panel) cells treated with VH298 for 2 h. B, HeLa and HFF cells
were treated with 100 μM of VH298 for 2 and 24 h. After 24 h treatment of 100 μM VH298, 400 μM of VH298 was introduced to HeLa cells for 2 h and
100 μM of VH298 to HFF cells for 2 h. A 2 h treatment with 400 μM of VH298 was also included in HeLa cells. C and D, HeLa cells were transfected with
nontargeting siRNA control (siNT) or VHL siRNA (siVHL). C, after 24 h, media were changed, and transfected cells were treated with 100 μM of VH298 for
indicated times. D, after 46 h, media were changed, and transfected cells were treated with indicated concentrations of VH298 for 2 h. Cell lysate of 786-O
was included as negative control for VHL. E, HeLa cells were treated with 3 and 24 h of 100 μM VH298. After 24 h treatments of 0.5% DMSO or 100 μM
VH298, cells were treated with proteasome inhibitor MG132 (20 μM), autophagy inhibitors chloroquine (CQ; 50 μM) or bafilomycin A1 (Baf A1; 50 nM) for
3 h. Protein levels were analyzed by immunoblotting using antibodies against HIF-1α, VHL, and β-actin, which acted as a loading control. The blots shown
are representative of three independent experiments. DMSO, dimethyl sulfoxide; HFF, human foreskin fibroblast; HIF-1α, hypoxia-inducible factor-1α.
VHL induction by inhibitorwould have decreased. HIF-1α protein levels were monitored
2 h after the subsequent addition of VH298 (Fig. 4B). Although
HIF-1α increased slightly, the addition of more VH298 did not
rescue the degraded HIF-1α to the same level as the initially
stabilized HIF-1α at 2 h in both HeLa and HFF (Fig. 4B) cells.
These results could indicate that the decrease of HIF-1α levels
in prolonged VH298 treatment was not because of insufficient
VH298 to inhibit VHL. However, it is also possible that the
extra-added inhibitor may be limited by cell permeability andso may still be insufficient to fully saturate intracellular VHL,
particularly given the significantly increased VHL levels under
those conditions. Therefore, we next investigated whether the
VH298-induced HIF-1α is degraded in a VHL-dependent
manner by performing siRNA-mediated knockdown of VHL
in HeLa cells, followed by VH298 treatment. In control siRNA-
treated cells, VH298 treatment gradually resulted in reduction
of HIF-1α levels, as expected. In contrast, under VHL knock-
down by siRNA, HIF-1α remained stabilized over the entireJ. Biol. Chem. (2021) 297(2) 100910 7
VHL induction by inhibitorcourse of 24-h compound treatment (Fig. 4C). This suggests
that the degradation of VH298-induced HIF-1α was indeed
mediated by VHL. Interestingly, siRNA knockdown of VHL
alone led to almost undetectable stabilization of HIF-1α (Fig. 4,
C and D), as previously shown (28). This is consistent with
siRNA knockdown not being able to completely remove all
endogenous VHLs and confirms that even very low amount of
the remaining VHL appears to be sufficient to efficiently pol-
yubiquitinate HIF-1α for proteasomal degradation.
We postulate that the high activity and catalytic efficiency of
VHL might explain the requirement of relatively high con-
centration of VHL inhibitor in order to observe detectable
levels of HIF-1α. To examine this hypothesis, a dose-
dependent VH298 treatment was performed with and
without siRNA-mediated VHL knockdown (Fig. 4D). In the
background of siRNA-mediated VHL knockdown, HIF-1α
levels could be detected already at 1 μM concentration of
VH298, in stark contrast to the negative control (siNT)
background where HIF-1α levels were undetected at the same
concentration of VH298 nor at 10-times higher concentration
of VH298 (Fig. 4D). Remarkably, a 10 μM inhibitor treatment
under VHL knockdown was found to achieve similar HIF-1α
stabilization as 100 μM VH298 in the negative control siRNA
background (Fig. 4D). The combination of VH298 and the
knockdown of VHL showed additive effect on accumulating
HIF-1α (Fig. 4D). Together, these data indicate that following
treatment with VHL inhibitor VH298, HIF-1α is initially sta-
bilized and then eventually degraded in a VHL-dependent
manner, as VHL level increases.
HIF-1α is known to be degraded via the proteasomal (35) as
well as lysosomal (36) pathways. To investigate the pathway
involved in the degradation of VH298-induced HIF-1α, HeLa
cells were first treated with VH298 for 24 h, followed by
proteasome inhibitor (MG132) or lysosome inhibitors (chlo-
roquine or bafilomycin A1) for the last 3 h. As expected, HIF-
1α was stabilized upon each of the three inhibitors (Fig. 4E).
After 24 h of VH298 treatment, MG132 rescued the degraded
HIF-1α to similar protein levels as 3 h treatment of VH298
(Fig. 4E). In contrast, lysosomal inhibitors were not as efficient;
both chloroquine and bafilomycin A1 increased HIF-1α to a
much lower extent compared with MG132. Altogether, these
data indicate that in prolonged VH298 treatment, the HIF-1α
proteins that accumulated in the presence of VHL inhibitor
VH298 are eventually degraded mainly via the proteasomal
pathway, in a VHL-dependent manner.Discussion
In this study, we investigated the selectivity of a VHL in-
hibitor VH032 at the proteomic level. Using quantitative TMT
labeling–based MS analysis, VH032 effects were compared
with those elicited by hypoxia and the broad-spectrum inhib-
itor IOX2. This analysis complemented our previous mRNA-
Seq analysis (16), as proteins that we identified changing
were also captured at the mRNA level. This is important, as
several global omics studies have reported a poor correlation
of mRNA to protein (37). Furthermore, some transcripts are8 J. Biol. Chem. (2021) 297(2) 100910induced at different stages of the hypoxia response, and pro-
tein translation and stability might also be altered in hypoxia.
Finally, we wanted to determine if the VHL inhibitor would
have off-target effects at the protein level, not identified at the
mRNA level. Our analysis confirmed that all HIF stabilizing
agents used share an overlap of proteins that are upregulated.
The vast majority of proteins identified as induced in our
analysis overlapped with our mRNA-Seq as predicted.
Furthermore, from the additional proteins identified, HIF-1α
and known HIF targets were also present. This suggests that
some HIF targets are induced at different times in the hypoxia
response and that a more dynamic analysis of mRNA and
protein would be required to fully cover all proteins induced
by the stimuli used. Although VHL has been shown to control
NF-κB activity (38–40), VH032 was found to target only the
HIF response, as no NF-Kb–dependent signature was identi-
fied in our proteomic dataset or indeed in our RNA-Seq
dataset (16). This further supports the specificity of the VHL
inhibitor used in this study.
Given the widespread use of VHL inhibitors and VHL-based
PROTACs as chemical tools to study biology, and as thera-
peutics, we were particularly interested in assessing target-
specific effects and potentially identify any off-target effects.
Our proteomics analysis revealed that VH032 is indeed
exquisitely specific and selective for VHL. In fact, the only
additional protein upregulated by VH032, not previously
shown to be induced by hypoxia, was VHL itself, as AMY1 had
previously been identified as a hypoxia-inducible protein (31).
Stabilization of VHL was also confirmed by using the more
potent inhibitor VH298. Further analysis revealed that this is
dependent on VHL isoform stabilization and not alterations in
mRNA levels. We have previously demonstrated direct binding
of VH298 to VHL, which in vitro resulted in increased thermal
stability both biophysically on the recombinant protein (41) as
well as in a cellular environment (13). Interestingly, our results
suggest that increased levels of VHL are responsible for
reduced HIF-1α levels observed following prolonged exposure
to VH298. Our data suggest that lowering the levels of VHL is
able to circumvent the reduction of HIF-1α.
There are several implications for these observations. First,
from a biological standpoint, it suggests that the HIF system
explores increased VHL protein level as yet another negative
feedback loop in place to prevent excess levels of the HIF
transcription factor for prolonged periods. This adds to the
known feedback loop of increased PHD2 and PHD3 protein
levels (42). Second, it implies that changes to VHL levels can in
itself regulate HIF-1α levels in cells. This is a concept that
needs further exploring. Although proline hydroxylation is in
most cases sufficient to maintain intracellular HIF-1α at low
levels (3), increasing VHL levels can provide an additional
mechanism to further reduce HIF-1α levels where necessary.
Thus far, this mechanism remains understudied, and thus,
future research is needed to investigate this further.
Our observations are also relevant to the pharmacology of
VHL inhibitors such as VH298 or its derivatives as well as
VHL-based PROTAC degraders. This is important given the
wide use of these compounds as tools to study biology and the
VHL induction by inhibitorinterest in their therapeutic development. VH298 has been
shown to improve wound healing (18) and also tendon healing
(17) in a rat model of injury. Other potential uses could be
anemia and mitochondrial dysfunction, where HIF stabiliza-
tion has been shown to be of benefit (43, 44). Our results
demonstrating high target specificity of VH298 and feedback
leading to reduced HIF-1α levels upon prolonged inhibitor
treatment suggest that the use of a medicinal derivative of this
chemical probe in these conditions could be highly recom-
mended, as it would be predicted to have low side effects in its
response. However, further analysis is now needed in vivo in
these pathological conditions to firmly establish this possibil-
ity. With regard to PROTACs, to our knowledge, no study to
date has reported of increased VHL levels upon PROTAC
treatment. This may be in part because of the fact that VHL
protein levels tend not to be monitored during PROTAC
treatment, with the exception of homo-PROTACs and hetero-
PROTACs aimed at inducing E3 ligase degradation (28, 45). It
is also conceivable to imagine that VHL stabilization will not
usually be observed because of the substoichiometric mode of
action of PROTACs, working at sufficiently low concentration
to induce target protein degradation, as opposed to the
occupancy-based mode of action of inhibitors (19). Nonethe-
less, we advocate for the field to monitor intracellular protein
levels of VHL when using VHL-based PROTACs. Interest-
ingly, low intracellular expression of the E3 ligase VHL in
platelets has been invoked to explain and exploit the observed
reduced dose-limiting toxicity of VHL-based Bcl-xL PROTAC
degraders (46).
We exemplify a case where a potent protein–protein
interaction inhibitor can increase the intracellular levels of
its target protein, while leading to a decrease in substrate
recognition and hence enzyme activity. While this may not be
unprecedented, we were able to find only one other such
example in the literature: the enzyme thymidylate synthase,
which is induced upon stabilization by its inhibitor 5-fluoro-20-
deoxyuridine 50-monophosphate (47). When inhibiting meta-
bolic or signaling pathways, enzyme target inhibition is often
coupled to a feedback change in metabolite or substrate/
product level, which in turn increases the transcription and/or
the translation of the gene encoding for the enzyme target (48,
49). The net result is an increase in total target protein, leading
to inhibitor/drug resistance. Other mechanisms of increase
target level occur as a result of gene amplification (50) or
release of the enzyme from binding to its own mRNA (51).
Here, our results exclude transcriptional/translational upre-
gulation and instead indicate that protein stabilization is the
primary mechanism responsible for the increased intracellular
levels of VHL. The finding that VHL inhibitors stabilize their
target protein is consistent with current understanding of VHL
structure and function. It is well documented that VHL acts as
a tumor suppressor (6) and that the VHL protein has both
moderate thermal stability (Tm  47 C, see Refs. (13, 41)) and
moderate cellular half-life (4–6 h, see Fig. 3E herein). We
therefore hypothesize that VHL stabilization upon small-
molecule binding leads to a reduction in intracellular degra-
dation of VHL. We speculate that such protection away fromdegradation could be the result of oligomerization (to itself or
partner proteins), by sequestration to other cellular compart-
ments, or by stabilizing flexible and disordered regions on the
VHL protein that normally confer its instability. Elucidating
the detailed mechanism by which VHL inhibitors stabilize
VHL warrants further mechanistic investigation in the future.
In conclusion, this work demonstrates the high specificity of
VHL inhibitors VH032 and VH298 and that these inhibitors
increase intracellular levels of their own target protein VHL, as
a result of protein binding and stabilization. This has impor-
tant implications for the pharmacology of VHL inhibitors and
potentially VHL-based PROTAC degraders. We suggest that
chronic long-term use of VHL inhibitors might benefit from
our newly identified VHL stabilization, and therefore, phar-
macological VHL blockade might not be as detrimental to cells
or organisms as previously thought.Experimental procedures
Cell culture and hypoxia induction
Human cervix carcinoma cells HeLa and HFF cells were
obtained from American Type Culture Collection and propa-
gated in Dulbecco’s modified Eagle’s medium (supplemented
with 10% fetal bovine serum, L-glutamine, and 100 μg/ml of
penicillin/streptomycin) at 37 C. Cell lines were routinely
tested for mycoplasma contamination using MycoAlert kit
from Lonza.Hypoxia treatment
For hypoxia induction, cells were incubated at 1% O2 in an
InVIVO 300 hypoxia workstation (Ruskin Technologies). In
order to prevent reoxygenation, cells were lysed for protein
extraction in the hypoxia workstation.Compound treatments
DMSO was used as vehicle control. The proteasome in-
hibitor MG132 was obtained from Merck/Millipore and used
at the final concentration of 20 μM for 3 h. PHD inhibitors
IOX2 and FG-4592 were purchased from Selleckchem. VHL
inhibitors VH032, VH298, and nonbinding epimer cisVH298
were synthesized by a group member of our laboratory
(13, 14). Compounds were added to cells for indicated length
of time. Chloroquine (Merck) and bafilomycin A1 (Sell-
eckchem) were added to cells for 3 h at 50 μM and 50 nM,
respectively.siRNA transfections
siRNA oligonucleotides were purchased from Eurofins/
MWG and used in a stock concentration of 20 μM. siRNAs
were transfected using INTERFERin from Polyplus according
to the manufacturer’s instructions. The oligonucleotide se-
quences used for siRNA knockdown are the following ones:
siNT (nontargeting): 50-AAC AGU CGC GUU UGC GAC
UGG-30
siVHL: 50-GGA GCG CAU UGC ACA UCA ACG-30J. Biol. Chem. (2021) 297(2) 100910 9
VHL induction by inhibitorImmunoblotting
Cells were lysed in radioimmunoprecipitation buffer
(50 mM Tris, pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, 250 M Na3VO4, 10 mM NaF, and a
protease inhibitor cocktail [Roche]) per 10 ml buffer. Proteins
were resolved using SDS-PAGE, transferred onto poly-
vinylidene difluoride membranes in a semidry transfer system
(BIORAD), and detected using primary antibodies, with
β-actin as loading controls in mammalian cells.
Primary antibodies were used at following dilutions for
mammalian cells: anti-HIF-1α (BD Biosciences; 610958; 1:1000
dilution), anti-VHL (Cell Signaling; #2738; 1:1000 dilution;
product is discontinued), anti-VHL (Cell Signaling Technol-
ogy; #68547; 1:1000 dilution), and anti-β-actin (Cell Signaling
Technology; #3700s; 1:10,000 dilution). Following incubation
with a horseradish peroxidase–conjugated secondary antibody
(Cell Signaling), chemiluminescence (Pierce) was used for
immunodetection.
Coimmunoprecipitation
HeLa cells were lysed in radioimmunoprecipitation buffer as
aforementioned. About 300 μg of cell lysates were used per
immunoprecipitation condition. Protein lysates were incu-
bated with 2 μg of HIF-1α antibody (Santa Cruz; sc-53546) or
2 μg of mouse IgG control antibody (Sigma) in a rotating
platform at 4 C overnight. About 20 μl of packed protein-G-
sepharose beads (Pierce) were used to recover the immuno-
complexes, by incubation in a rotating platform for 1.5 h at
4 C. Beads were washed with 1× PBS buffer thrice. The
complexes were eluted from beads with SDS-loading buffer
and resolved as described previously by immunoblotting.
Quantitative real-time PCR
For mammalian cells, RNA was extracted using the RNeasy
Mini Kit (Qiagen) according to manufacturer’s protocol. RNA
was reverse transcribed using the iScript cDNA Synthesis Kit
(Bio-Rad Laboratories). Real-time PCR was performed in
triplicates using PerfeCTa SYBR Green FastMix (Quanta
Biosciences) in C1000 Touch Thermal Cycler (Bio-Rad Lab-
oratories). mRNA levels were calculated based on averaged
cycle threshold values and normalized to β-actin mRNA levels.
Primer sequences used are listed herewith:
VHL: Forward, 50-CCT TGG CTC TTC AGA GAT G-30
VHL: Reverse, 50-TGA CGA TGT CCA GTC TCC T-30
β-actin: Forward, 50-CTC TTC CAG CCT TCC TTC CTG-30
β-actin: Reverse, 50-GAA GCA TTT GCG GTGGAC GAT-30
Protein sample preparation and TMT labeling–based MS
HeLa cells were treated with 0.5% DMSO, hypoxia (1% O2),
250 μM IOX2, and 250 μM VH032 for 24 h. HeLa cells were
lysed in 4% SDS in 100 mM Tris–HCl, pH 8.5 and 1× protease
inhibitor (one cocktail tablet [Roche] per 10 ml of lysis buffer).
Lysates were first sonicated for six cycles of 30 s on/30 s off
under low-power setting with Bioruptor Twin (Diagenode)
and then centrifuged at 17,000g for 10 min at 4 C. Samples
could be stored at −80 C freezer. The experiments were10 J. Biol. Chem. (2021) 297(2) 100910performed in two biological replicates. The protein samples
were further processed, including reduction, alkylation,
digestion, desalting, TMT labeling, and fractionation accord-
ing to the one previously described (24). TMT 10plex Isobaric
Label Reagent Set (Thermo Fisher Scientific) was used despite
two biological replicates of four conditions (a total of eight
samples), as a duplicate of another condition was included in
the MS that was not part of this project. The forth duplicate
treatment was VHL inhibitor VH101, which however led to
confounding the results because of its cytotoxicity, so is not
included (14). Samples were labeled according to that indi-
cated in Figure 1A.
Nanoflow LC MS/MS analysis
Analysis of peptides was performed on a Q Exactive HF
Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo
Fisher Scientific) coupled with a Dionex UltiMate 3000
RSLCnano Systems (Thermo Fisher Scientific). The peptides
from each fraction were separated using a mix of buffer A (2%
acetonitrile and 0.1% formic acid in Milli-Q water [v/v]) and
buffer B (80% acetonitrile and 0.08% formic acid in Milli-Q
water [v/v]). The peptides were eluted from the column at a
constant flow rate of 300 nl/min with a linear gradient from
95% buffer A to 40% buffer B in 122 min and then to 98%
buffer B by 132 min. The column was then washed with 95%
buffer B for 15 min and re-equilibrated in 98% buffer A for
32 min. The Q Exactive HF Hybrid Quadrupole-Orbitrap
Mass Spectrometer was used in data-dependent mode. A
scan cycle comprised MS1 scan (m/z range from 335 to 1800,
with a maximum ion injection time of 50 ms, a resolution of
120,000, and an automatic gain control value of 3 × 106) fol-
lowed by 15 sequential-dependant MS2 scans (with an isola-
tion window set to 1.2 Da, resolution at 60,000, maximum ion
injection time at 200 ms, and AGC 1 × 105). To ensure mass
accuracy, the mass spectrometer was calibrated on the first day
that the runs are performed.
Data processing and database searching
Raw MS data from 22 fractions were searched against Swiss-
Prot database (March 8, 2015; Homo sapiens; 54,7964 se-
quences—after human taxonomy filter applied—20,203) using
the MASCOT software (Matrix Science Ltd, version 2.2)
through Proteome Discover software (Thermo Fisher Scienti-
fic, version 1.4). Mascot significance threshold was set to 0.05.
Trypsin/P was specified as the cleavage enzyme allowing up to
two missed cleavages. The database search included the
following parameters: MS1 Tolerance: 10 ppm, MS2 Toler-
ance: 0.06 Da, fixed modification: Carbamidomethyl (C).
Variable Modification: Oxidation (M), Dioxidation (M), Acetyl
(N-term), Gln->pyro-Glu (N-term Q), hydroxyl (P),
TMT10plex (N-term), and TMT10plex (K). The data were
filtered by applying a 1% false discovery rate. Quantified pro-
teins were filtered if the absolute fold-change difference be-
tween conditions to respective DMSO of the same biological
replicate was ≥1.3 for upregulated proteins and ≤0.7 for
downregulated proteins.
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